Cefozopran (CAS 113359-04-9) Suppliers and Product Information

Cefozopran is a fourth-generation cephalosporin antibiotic with an imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl group at position 3 and a (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl amino side group at position 7. It belongs to the classes of cephalosporins, thiadiazoles, and imidazopyridazines.

Antimicrobial activity: Cefozopran has activity similar to ceftazidime but is more active against methicillin-susceptible staphylococci (MIC ≤1mg/L). It shows effectiveness against various Gram-negative species, including E. coli (MIC 0.25 mg/L), K. pneumoniae (MIC 1 mg/L), and P. aeruginosa (MIC 1-8 mg/L). However, it has poor activity against Acinetobacter spp., S. maltophilia, and B. fragilis group.

Pharmacokinetics: A 20-minute infusion of 1.5 g achieves a plasma concentration of around 125 mg/L at the end of infusion. Almost 90% of the dose is excreted in the urine over 24 hours, with a mean terminal half-life of around 2 hours.

Frequently Asked Questions about Cefozopran

Q: What is the primary use of Cefozopran?

A: Cefozopran is primarily used as an antibacterial agent. It is a fourth-generation cephalosporin antibiotic effective against various bacterial infections, particularly those caused by Gram-negative bacteria.

Q: How is Cefozopran administered?

A: Cefozopran is typically administered intravenously. In clinical studies, it has been given as a 20-minute infusion.

Q: Are there any notable side effects of Cefozopran?

A: The adverse reactions of Cefozopran appear to be typical of those observed with other group 6 cephalosporins. However, as with all medications, it's important to consult with a healthcare professional for a complete list of potential side effects and drug interactions.

Q: Where is Cefozopran currently available?

A: According to the information provided, Cefozopran is available in Japan.